文献速递心律失常血脂与心血管预防

英国基层医疗中阵发性房颤的抗凝治疗现状与趋势

The treatment of paroxysmal atrial fibrillation in UK primary care.
PubMed 文献 · Heart · 2017-06-01

该研究基于英国基层医疗数据库,分析2000至2015年间阵发性房颤与持续性/永久性房颤患者接受抗凝治疗的比例差异及趋势。结果显示,阵发性房颤患者抗凝治疗率虽随时间改善,但2015年仍比其它类型房颤患者低约20%。

要点

  • 阵发性房颤诊断比例从2000年7.4%升至2015年14.0%。
  • CHADS2≥1的阵发性房颤患者抗凝比例从18.8%升至56.2%。
  • 2015年阵发性房颤患者抗凝可能性仍比其它房颤低约20%。

核心结论

  • 2000年符合条件的阵发性房颤患者接受抗凝治疗的可能性是其它房颤患者的一半,至2015年改善至仍低约20%。

研究设计与样本

  • 基于英国健康改善网络数据库648家全科诊所的16次年度横断面分析,纳入≥35岁、注册至少1年的房颤患者。

主要发现

  • 阵发性房颤诊断比例从2000年7.4%(95%CI 7.0-7.8)升至2015年14.0%(95%CI 13.7-14.3)。
  • CHADS2≥1的阵发性房颤患者抗凝比例从18.8%(95%CI 16.4-21.4)升至56.2%(95%CI 55.0-57.3)。
  • CHADS2≥1的其它房颤患者抗凝比例从34.2%(95%CI 33.3-35.0)升至69.4%(95%CI 68.9-69.8)。
  • 阵发性房颤相对于其它房颤的治疗相对风险(RR)从0.48(95%CI 0.42-0.55)升至0.76(95%CI 0.74-0.77)。

关键数值与推荐

  • 英国与欧洲指南推荐:所有卒中风险增加的房颤患者均应接受抗凝治疗,无论房颤类型。

临床怎么用

  • 基层医生应识别阵发性房颤患者并按照指南基于卒中风险给予抗凝,避免因房颤类型而区别对待。

局限性

  • 研究为观察性横断面分析,仅反映处方行为,未报告临床结局或用药依从性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To determine whether patients with paroxysmal atrial fibrillation (AF) are less likely to be treated with anticoagulants than patients with persistent/permanent AF and to investigate trends in treatment between 2000 and 2015. UK and European guidelines recommend that anticoagulants are offered to all patients with AF at increased risk of stroke, irrespective of AF type. METHODS: Sixteen sequential cross-sectional analyses from 2000 to 2015 were carried out with index dates on 1st of May each year. The data source was primary care data from 648 practices across the UK contributing to The Health Improvement Network database. All patients with a diagnosis of AF aged ≥35 years and registered for at least 1 year were included. The main outcome measure was prescription of anticoagulant medication. RESULTS: The proportion of patients with AF with a diagnosis of paroxysmal AF increased from 7.4% (95% CI 7.0 to 7.8) in 2000 to 14.0% (95% CI 13.7 to 14.3) in 2015. Among patients with a CHADS2 score of ≥1, between 2000 and 2015 the proportion prescribed anticoagulants increased from 18.8% (95% CI 16.4 to 21.4) to 56.2% (95% CI 55.0 to 57.3) and from 34.2% (95% CI 33.3 to 35.0) to 69.4% (95% CI 68.9 to 69.8) in patients with paroxysmal and other (persistent/permanent) AF, respectively; RR for treatment of patients with paroxysmal AF compared with patients with other AF increased from 0.48 (95% CI 0.42 to 0.55) to 0.76 (95% CI 0.74 to 0.77). Adjusting for age, sex, Townsend score and presence or absence of contraindications had little effect on the results. CONCLUSIONS: In 2000, eligible patients with paroxysmal AF were half as likely to be treated with anticoagulants as patients with other AF; this has improved over time, but in 2015, eligible patients with paroxysmal AF were still around 20% less likely to be prescribed anticoagulant medication.

来源:Heart,查看原文。版权归原作者所有。

引用

  1. Isaew A, Adderley NJ, Ryan R, et al. The treatment of paroxysmal atrial fibrillation in UK primary care. Heart. 2017. PMID: 28572399. doi:10.1136/heartjnl-2016-310927

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。